Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well zanubrutinib and lisocabtagene maraleucel (liso-cel) work
together in treating patients with Richter's syndrome. Richter's syndrome occurs when chronic
lymphocytic leukemia and/or small lymphocytic leukemia transforms into an aggressive
lymphoma, which is a cancer of the lymph nodes. Zanubrutinib is a class of medication called
a kinase inhibitor. These drugs work by preventing the action of abnormal proteins that tell
cancer cells to multiply, which helps stop the spread of cancer. Liso-cel is a type of
treatment known as chimeric antigen receptor (CAR) T cell therapy. CAR T-cell therapy is a
type of treatment in which a patient's T cells (a type of immune system cell) are changed in
the laboratory so they will attack cancer cells. T cells are taken from a patient's blood.
Then the gene for a special receptor that binds to a certain protein on the patient's cancer
cells is added to the T cells in the laboratory. The special receptor is called a chimeric
antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and
given to the patient by infusion for treatment of certain cancers. Giving zanubrutinib and
liso-cell together may kill more cancer cells in patients with Richter's syndrome.